The new 3B-NEO service uses whole exome and whole genome sequencing to identify risks for serious childhood-onset disorders before symptoms appear.
3billion, a genomic diagnostics company, launched 3B-NEO, a genomic newborn screening service designed to identify genetic risks before symptoms appear and support earlier medical intervention.
The service focuses on 595 genes associated with serious childhood-onset conditions where early medical intervention, monitoring, or treatment may improve patient outcomes. 3B-NEO was developed to prioritize actionable findings that support clinical decision-making for physicians and families rather than providing an exhaustive list of all genetic findings.
While traditional newborn screening programs typically rely on biochemical markers to assess a limited number of conditions, 3B-NEO utilizes genomic sequencing to identify risks for inherited metabolic disorders, immunologic disorders, neuromuscular diseases, cardiovascular conditions, and other pediatric genetic disorders.
“Genomic newborn screening creates the greatest value when it enables action before symptoms appear,” says Changwon Keum, CEO of 3billion, in a release. “Advances in genomic medicine are making it increasingly possible to identify health risks early and prepare appropriate medical interventions before irreversible complications develop. Through 3B-NEO, we aim to help healthcare providers and families make earlier, more informed decisions that can improve long-term health outcomes.”
Testing Options and Laboratory Operations
The service is available through two testing options: a whole-exome sequencing-based standard test and a whole-genome sequencing-based premium test. Results for both options are typically delivered within approximately two weeks after the laboratory receives the sample.
The service is designed for use by hospitals, obstetrics practices, and pediatric clinics. According to the company, healthcare providers can offer the screening without establishing in-house genomic testing infrastructure. Parents may request the testing through participating providers, subject to clinical review and approval.
Based in Seoul, South Korea, and Austin, Texas, 3billion provides AI-powered genomic interpretation and rare disease diagnostic services to healthcare professionals in more than 75 countries. As part of its growth strategy in the US, the company is preparing local laboratory operations at its Austin subsidiary to support domestic healthcare providers and patients.
The launch of 3B-NEO is part of the company’s effort to expand its precision medicine platform beyond rare disease diagnosis into proactive genomic healthcare. The company says it plans to collaborate with healthcare providers globally, particularly in markets where access to advanced genetic testing is currently limited but the need for early diagnosis is increasing.
ID 18314167 | Healthcare © Petrina Calabalic | Dreamstime.com
